Evaluation of the antitumor efficacy of the new antigenic receptor targeting the PD-L1 molecule.

The aim of the project is to try to combine these two novel therapeutic concepts by evaluating the efficacy of the novel CAR receptor targeting PD-LI on cancer cells or tumor stromal. For this purpose, the following research tasks are planned: Optimization of CAR-anly-PD-LI receptor expression methods in effector cells. Comparison of the anti-tumor efficacy of CAR-T and CAR-NK cells against tumor cells showing different levels of PD-LI expression. Use the synNotch strategy to achieve specific CAR-anly-PD-LI action in the vicinity of tumor cells. Evaluation of the efficacy of cytotoxic cells expressing CAR-anti-PD-Ll receptor in vivo. Expected results: At the present time, intensive research is being carried out into the use of receptor technology to fight as many types of cancer as possible. The focus was on, inter alia, searching for new therapeutic targets; however, it is becoming increasingly clear that cancer cell resistance is a significant problem in this therapy. The project has the potential to make significant progress on both of these aspects by providing conceptual evidence for the effective and safe targeting of effector cells to a therapeutic target, extremely important in tumor resistance to immunotherapy. The research results will contribute in the future to the optimization of therapeutic regimens used in oncology with the use of modern molecularly targeted immunotherapies.